Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo

Drug Metabolism and Disposition

Volumn 38, Issue 9, 2010, Pages 1449-1455

  Donato, M Teresa ^a,b,c   Hallifax, David ^d   Picazo, Laura ^a   Castell, José V ^a,b,c   Houston, J Brian ^d   Gomez Lechón, M José ^a,b   Lahoz, Agustin ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPRAZOLAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; MIDAZOLAM; PHENACETIN; TOLBUTAMIDE;

ARTICLE; CELL DENSITY; CELL STRAIN HEPG2; CELL SUSPENSION; CONTROLLED STUDY; CRYOPRESERVATION; DRUG CLEARANCE; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTRATE INDUCED RESPIRATION;

ADENOVIRIDAE; ALPRAZOLAM; BASE SEQUENCE; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HEPATOCYTES; HUMANS; MIDAZOLAM; PHENACETIN; TOLBUTAMIDE;

ADENOVIRIDAE;

EID: 77955998988     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033605     Document Type: Article

References (43)

1. Ansede JH and Thakker DR (2004) High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci 93:239-255.
2. Aoyama K, Yoshinari K, Kim HJ, Nagata K, and Yamazoe Y (2009) Simultaneous expression of plural forms of human cytochrome P450 at desired ratios in HepG2 cells: adenovirus-mediated tool for cytochrome P450 reconstitution. Drug Metab Pharmacokinet 24:209-217.
3. Bachmann K, Byers J, and Ghosh R (2003) Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica 33:475-483.
4. Bai J and Cederbaum AI (2004) Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2 cells to acetaminophen induced cytotoxicity. Mol Cell Biochem 262:165-176.
5. Becker TC, Noel RJ, Coats WS, Gómez-Foix AM, Alam T, Gerard RD, and Newgard CB (1994) Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43:161-189.
6. Bort R, Macé K, Gómez-Lechón MJ, Pfeifer A, and Castell JV (1999) High expression of human CYP2C in immortalized human liver epithelial cells. Toxicol In Vitro 13:633-638. (Pubitemid 29354189)
7. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
8. Castell JV, Gómez-Lechón MJ, Jover R, and Lahoz A (2005), inventors; Advanced In Vitro Cell Technology, assignees. Method for obtaining a singular cell model capable of reproducing in vitro the metabolic idiosyncrasy of humans. World Patent WO2005068611. 2005 July 28.
9. Castell JV, Hernández D, Gómez-Foix AM, Guillén I, Donato T, and Gómez-Lechón MJ (1997) Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Ther 4:455-464.
10. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:180-235.
11. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
12. Donato MT, Castell JV, and Gómez-Lechón MJ (1999) Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models. J Hepatol 31:542-549.
13. Donato MT, Gómez-Lechón MJ, and Castell JV (1993) A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 213:29-33.
14. Donato MT, Lahoz A, Jiménez N, Pérez G, Serralta A, Mir J, Castell JV, and Gómez-Lechón MJ (2006) Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 34:1556-1562.
15. Ferrer-Martínez A, Riera A, Jiménez-Chillarón JC, Herrero P, Moreno F, and Gómez-Foix AM (2004) A glucose response element from the S. cerevisiae hexose transporter HXT1 gene is sensitive to glucose in human fibroblasts. J Mol Biol 338:657-667.
16. Gómez-Foix AM, Coats WS, Baqué S, Alam T, Gerard RD, and Newgard CB (1992) Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem 267:25129-25134.
17. Gonzalez FJ and Korzekwa KR (1995) Cytochromes P450 expression systems. Annu Rev Pharmacol Toxicol 35:369-390.
18. Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, and Houston JB (2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 23:533-539.
19. Hallifax D, Galetin A, and Houston JB (2008) Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 38:353-367.
20. Hallifax D and Houston JB (2009) Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro human experimental systems. Curr Drug Metab 10:307-321.
21. Hallifax D, Rawden HC, Hakooz N, and Houston JB (2005) Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 33:1852-1858. (Pubitemid 41697271)
22. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
23. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112.
24. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171. (Pubitemid 27191615)
25. Jover R, Hoffmann K, and Meyer UA (1996) Induction of 5-aminolevulinate synthase by drugs is independent of increased apocytochrome P450 synthesis. Biochem Biophys Res Commun 226:152-157.
26. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-506.
27. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
28. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
29. McGrory WJ, Bautista DS, and Graham FL (1988) A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163:614-617.
30. Naiki T, Nagaki M, Shidoji Y, Kojima H, and Moriwaki H (2004) Functional activity of human hepatoma cells transfected with adenovirus-mediated hepatocyte nuclear factor (HNF)-4 gene. Cell Transplant 13:393-403. (Pubitemid 39163084)
31. Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588.
32. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
33. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, and Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628.
34. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178.
35. Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, and Houston JB (2005) Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica 35:603-625.
36. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
37. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, and Gómez-Lechón MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505-520.
38. Stringer R, Nicklin PL, and Houston JB (2008) Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38:1313-1329.
39. Stringer RA, Strain-Damerell C, Nicklin P, and Houston JB (2009) Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 37:1025-1034.
40. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407. (Pubitemid 23320988)
41. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (1998) Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502-1507.
42. Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter R, and Monshouwer M (2005) An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216:154-167. (Pubitemid 41712005)
43. Zangar RC, Bollinger N, Verma S, Karin NJ, and Lu Y (2008) The nuclear factor-κB pathway regulates cytochrome P450 3A4 protein stability. Mol Pharmacol 73:1652-1658.